Amedisys (BMV:AMED *) - Aktienkurs, Nachrichten und Analyse

AMED * Aktienübersicht

Provides healthcare services in the United States.

AMED * grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	3/6
Künftiges Wachstum	3/6
Vergangene Leistung	1/6
Finanzielle Gesundheit	3/6
Dividenden	0/6

Belohnungen

48.5% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 62.12% pro Jahr

Risikoanalyse

Aktien sind hochgradig illiquide

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Die Gewinnspannen (0.1%) sind niedriger als im Vorjahr (6.3%)

Amedisys, Inc. Wettbewerber

Dr. Lal PathLabs

NSEI:LALPATHLAB

₹226.3b

Topchoice Medical

SHSE:600763

CN¥17.0b

Médica Sur. de

BMV:MEDICA B

Mex$4.1b

Medicover

OM:MCOV B

SEK 29.1b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Amedisys
Historische Aktienkurse
Aktueller Aktienkurs	US$1,566.00
52-Wochen-Hoch	US$2,030.00
52-Wochen-Tief	US$1,469.00
Beta	1.0
11 Monat Veränderung	0%
3 Monate Veränderung	n/a
1 Jahr Veränderung	n/a
33 Jahre Veränderung	-68.20%
5 Jahre Veränderung	n/a
Veränderung seit IPO	-30.71%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	AMED *	MX Healthcare	MX Markt
7D	0%	0.9%	-0.9%
1Y	n/a	-23.0%	-2.8%

Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie AMED * im Vergleich zur Branche MX Healthcare abschneidet.

Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie AMED * im Vergleich zum MX Markt abgeschnitten hat.

Preisvolatilität

Is AMED *'s price volatile compared to industry and market?
AMED * volatility
AMED * Average Weekly Movement	n/a
Healthcare Industry Average Movement	6.2%
Market Average Movement	4.3%
10% most volatile stocks in MX Market	6.7%
10% least volatile stocks in MX Market	2.4%

Stabiler Aktienkurs: AMED * hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von AMED * im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1982	20,000	Richard Ashworth	www.amedisys.com

Amedisys, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Amedisys im Vergleich zum Marktanteil des Unternehmens?
AMED * grundlegende Statistiken
Marktanteil	Mex$53.39b
Gewinn(TTM)	Mex$40.55m
Umsatz(TTM)	Mex$38.80b

1,317x

Kurs-Gewinn-Verhältnis

1.4x

Kurs-Umsatz-Verhältnis

Ist AMED * zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
AMED * Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$2.23b
Kosten der Einnahmen	US$1.76b
Bruttogewinn	US$468.15m
Sonstige Ausgaben	US$465.82m
Umsatz	US$2.33m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.071
Bruttomarge	21.00%
Nettogewinnspanne	0.10%
Schulden/Eigenkapital-Verhältnis	35.6%

Wie hat sich AMED * auf lange Sicht entwickelt?

Historische Performance und Vergleiche

AMED * Aktienübersicht

Belohnungen

Risikoanalyse

Amedisys, Inc. Wettbewerber

NSEI:LALPATHLAB

₹226.3b

SHSE:600763

CN¥17.0b

BMV:MEDICA B

Mex$4.1b

OM:MCOV B

SEK 29.1b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Insufficient new directors

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Insufficient new directors

Recent updates

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Insufficient new directors

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

High number of new directors

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

High number of new directors

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

High number of new directors

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

High number of new directors

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment deteriorated over the past week

Lead Independent Director recently bought Mex$3.0m worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Investor sentiment improved over the past week

High number of new directors

High number of new directors

Independent Director recently sold Mex$42m worth of stock

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

Investor sentiment deteriorated over the past week

High number of new directors

President & COO recently sold Mex$1.5m worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold Mex$10m worth of stock

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

Independent Director recently bought Mex$5.3m worth of stock

Revenue misses expectations

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Erträge & Einnahmen